메뉴 건너뛰기




Volumn 18, Issue 2, 2013, Pages 115-122

The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor; Hepatocyte growth factor; MET; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

5 (2, 6 DICHLOROBENZYLSULFONYL) 3 [3, 5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1, 3 DIHYDRO 2H INDOL 2 ONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; FICLATUZUMAB; GEFITINIB; H 224G11; MGCD 265; N (3 CHLOROPHENYL) 3 [3, 5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2, 3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NAVELBINE; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SGX 523; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

EID: 84874345305     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0262     Document Type: Review
Times cited : (64)

References (57)
  • 1
    • 84874352705 scopus 로고    scopus 로고
    • Surveillance, Epidemiology, and End Results, Table 1.1, All Races, By Sex. Available at, accessed September 4,
    • Surveillance, Epidemiology, and End Results. Table 1.1. Estimated New Cancer Cases and Deaths for 2010. All Races, By Sex. Available at http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.01.pdf, accessed September 4, 2012.
    • (2012) Estimated New Cancer Cases and Deaths For 2010
  • 2
    • 13944276728 scopus 로고    scopus 로고
    • Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
    • Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488.
    • (2005) Cancer Res , vol.65 , pp. 1479-1488
    • Ma, P.C.1    Jagadeeswaran, R.2    Jagadeesh, S.3
  • 3
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small- cell lung cancer
    • Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small- cell lung cancer. N Engl J Med 2006;355:2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 4
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small- cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small- cell lung cancer. J Clin Oncol 2008;26:3543-3551.
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    von Pawel, J.3
  • 5
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 6
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues, P.J.2    Ciuleanu, T.3
  • 7
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 8
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
    • (2010) N Engl J Med , vol.362 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 9
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non- small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non- small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
    • (2010) Lancet Oncol , vol.11 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3
  • 10
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-0802): A multi- centre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-0802): A multi- centre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 11
    • 38049150665 scopus 로고    scopus 로고
    • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    • Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 20932-20937
    • Bean, J.1    Brennan, C.2    Shih, J.Y.3
  • 12
    • 73349096261 scopus 로고    scopus 로고
    • Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Hammerman PS, Jänne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009;15:7502-7509.
    • (2009) Clin Cancer Res , vol.15 , pp. 7502-7509
    • Hammerman, P.S.1    Jänne, P.A.2    Johnson, B.E.3
  • 13
    • 69349088824 scopus 로고    scopus 로고
    • Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials
    • Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-5273.
    • (2009) Clin Cancer Res , vol.15 , pp. 5267-5273
    • Jackman, D.M.1    Miller, V.A.2    Cioffredi, L.A.3
  • 15
    • 33751292685 scopus 로고    scopus 로고
    • Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    • Balak MN, Gong Y, Riely GJ et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-6501.
    • (2006) Clin Cancer Res , vol.12 , pp. 6494-6501
    • Balak, M.N.1    Gong, Y.2    Riely, G.J.3
  • 16
    • 58149333768 scopus 로고    scopus 로고
    • Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    • Bean J, Riely GJ, Balak M et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14:7519-7525.
    • (2008) Clin Cancer Res , vol.14 , pp. 7519-7525
    • Bean, J.1    Riely, G.J.2    Balak, M.3
  • 17
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3
  • 18
    • 84863234710 scopus 로고    scopus 로고
    • Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer
    • Wang W, Li Q, Takeuchi S et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 2012;18:1663-1671.
    • (2012) Clin Cancer Res , vol.18 , pp. 1663-1671
    • Wang, W.1    Li, Q.2    Takeuchi, S.3
  • 19
    • 74949142595 scopus 로고    scopus 로고
    • Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer
    • Yamada T, Matsumoto K, Wang W et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010;16:174-183.
    • (2010) Clin Cancer Res , vol.16 , pp. 174-183
    • Yamada, T.1    Matsumoto, K.2    Wang, W.3
  • 20
    • 84863338076 scopus 로고    scopus 로고
    • Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer
    • Yamada T, Takeuchi S, Kita K et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012;7:272-280.
    • (2012) J Thorac Oncol , vol.7 , pp. 272-280
    • Yamada, T.1    Takeuchi, S.2    Kita, K.3
  • 21
    • 56449089812 scopus 로고    scopus 로고
    • Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    • Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487.
    • (2008) Cancer Res , vol.68 , pp. 9479-9487
    • Yano, S.1    Wang, W.2    Li, Q.3
  • 22
    • 81755185464 scopus 로고    scopus 로고
    • Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort
    • Yano S, Yamada T, Takeuchi S et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011;6:2011-2017.
    • (2011) J Thorac Oncol , vol.6 , pp. 2011-2017
    • Yano, S.1    Yamada, T.2    Takeuchi, S.3
  • 23
    • 80555139776 scopus 로고    scopus 로고
    • Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)
    • Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(suppl 18):CRA7506.
    • (2011) J Clin Oncol , vol.29 , Issue.18 SUPPL.
    • Kris, M.G.1    Johnson, B.E.2    Kwiatkowski, D.J.3
  • 24
    • 58049192366 scopus 로고    scopus 로고
    • MET as a target for treatment of chest tumors
    • Cipriani NA, Abidoye OO, Vokes E et al. MET as a target for treatment of chest tumors. Lung Cancer 2009;63:169-179.
    • (2009) Lung Cancer , vol.63 , pp. 169-179
    • Cipriani, N.A.1    Abidoye, O.O.2    Vokes, E.3
  • 25
    • 0038724909 scopus 로고    scopus 로고
    • c-Met: Structure, functions and potential for therapeutic inhibition
    • Ma PC, Maulik G, Christensen J et al. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-325.
    • (2003) Cancer Metastasis Rev , vol.22 , pp. 309-325
    • Ma, P.C.1    Maulik, G.2    Christensen, J.3
  • 26
    • 33746504571 scopus 로고    scopus 로고
    • Invasive growth: A MET-driven genetic programme for cancer and stem cells
    • Boccaccio C, Comoglio PM. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-645.
    • (2006) Nat Rev Cancer , vol.6 , pp. 637
    • Boccaccio, C.1    Comoglio, P.M.2
  • 27
    • 0035845485 scopus 로고    scopus 로고
    • Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase
    • Furge KA, Kiewlich D, Le P et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001;98:10722-10727.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , pp. 10722-10727
    • Furge, K.A.1    Kiewlich, D.2    Le, P.3
  • 28
    • 0028318915 scopus 로고
    • Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: Evidence for rapid decay of the 8 kb c-MET transcript
    • Moghul A, Lin L, Beedle A et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: Evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 1994;9:2045-2052.
    • (1994) Oncogene , vol.9 , pp. 2045-2052
    • Moghul, A.1    Lin, L.2    Beedle, A.3
  • 29
    • 0037478437 scopus 로고    scopus 로고
    • Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
    • Pennacchietti S, Michieli P, Galluzzo M et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-361.
    • (2003) Cancer Cell , vol.3 , pp. 347-361
    • Pennacchietti, S.1    Michieli, P.2    Galluzzo, M.3
  • 30
    • 55449116539 scopus 로고    scopus 로고
    • Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
    • Okuda K, Sasaki H, Yukiue H et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-2285.
    • (2008) Cancer Sci , vol.99 , pp. 2280-2285
    • Okuda, K.1    Sasaki, H.2    Yukiue, H.3
  • 31
    • 63849163410 scopus 로고    scopus 로고
    • Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients
    • Cappuzzo F, Marchetti A, Skokan M et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-1674.
    • (2009) J Clin Oncol , vol.27 , pp. 1667-1674
    • Cappuzzo, F.1    Marchetti, A.2    Skokan, M.3
  • 32
    • 33947207989 scopus 로고    scopus 로고
    • Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival
    • Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-2088.
    • (2007) Cancer Res , vol.67 , pp. 2081-2088
    • Lutterbach, B.1    Zeng, Q.2    Davis, L.J.3
  • 33
    • 77953458271 scopus 로고    scopus 로고
    • ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity
    • Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-1553.
    • (2010) Mol Cancer Ther , vol.9 , pp. 1544-1553
    • Munshi, N.1    Jeay, S.2    Li, Y.3
  • 34
    • 84874387981 scopus 로고    scopus 로고
    • First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: II) in vivo activity
    • 2009
    • Goetsch L, Lepecquet A-M, Geronimi F et al. First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: II) in vivo activity. Proc Am Assoc Cancer Res 2009;2009:2792.
    • (2792) Proc Am Assoc Cancer Res , pp. 2009
    • Goetsch, L.1    Lepecquet, A.-M.2    Geronimi, F.3
  • 35
    • 34248575532 scopus 로고    scopus 로고
    • A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
    • Puri N, Khramtsov A, Ahmed S et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007;67:3529-3534.
    • (2007) Cancer Res , vol.67 , pp. 3529-3534
    • Puri, N.1    Khramtsov, A.2    Ahmed, S.3
  • 36
    • 42249107319 scopus 로고    scopus 로고
    • A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
    • Yang Y, Wislez M, Fujimoto N et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008;7:952-960.
    • (2008) Mol Cancer Ther , vol.7 , pp. 952-960
    • Yang, Y.1    Wislez, M.2    Fujimoto, N.3
  • 37
    • 79952259564 scopus 로고    scopus 로고
    • Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    • Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-1180.
    • (2011) Clin Cancer Res , vol.17 , pp. 1169-1180
    • Arcila, M.E.1    Oxnard, G.R.2    Nafa, K.3
  • 38
    • 79953118839 scopus 로고    scopus 로고
    • Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    • Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
    • (2011) Sci Transl Med , Issue.3
    • Sequist, L.V.1    Waltman, B.A.2    Dias-Santagata, D.3
  • 40
    • 34249984736 scopus 로고    scopus 로고
    • HER3 and mutant EGFR meet MET
    • Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007;13:675-677.
    • (2007) Nat Med , vol.13 , pp. 675-677
    • Arteaga, C.L.1
  • 41
    • 77954586493 scopus 로고    scopus 로고
    • Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis
    • Benedettini E, Sholl LM, Peyton M et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010; 177:415-423.
    • (2010) Am J Pathol , vol.177 , pp. 415-423
    • Benedettini, E.1    Sholl, L.M.2    Peyton, M.3
  • 42
    • 84874380268 scopus 로고    scopus 로고
    • Kyowa Hakko Kirin Co. Ltd.,Tokyo, Japan. Data on file
    • Kyowa Hakko Kirin Co. Ltd.,Tokyo, Japan. Data on file.
  • 43
    • 79952272155 scopus 로고    scopus 로고
    • Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice
    • Stabile LP, Rothstein ME, Keohavong P et al. Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers (Basel) 2010;2:2153-2170.
    • (2010) Cancers (Basel) , vol.2 , pp. 2153-2170
    • Stabile, L.P.1    Rothstein, M.E.2    Keohavong, P.3
  • 44
    • 77956296140 scopus 로고    scopus 로고
    • MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth
    • Zhang YW, Staal B, Essenburg C et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70: 6880-6890.
    • (2010) Cancer Res , vol.70 , pp. 6880-6890
    • Zhang, Y.W.1    Staal, B.2    Essenburg, C.3
  • 45
    • 84891560269 scopus 로고    scopus 로고
    • Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in phase II clinical development, in combination with an EGFR inhibitor
    • Fournel M, Dupont I, Bonfils C et al. Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in phase II clinical development, in combination with an EGFR inhibitor. Proc Am Assoc Cancer Res 2010; 70(suppl 1):3612.
    • (2010) Proc Am Assoc Cancer Res , vol.70 , Issue.1 SUPPL. , pp. 3612
    • Fournel, M.1    Dupont, I.2    Bonfils, C.3
  • 46
    • 77952119744 scopus 로고    scopus 로고
    • Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: Impact of preclinical studies on clinical trial design
    • Janne PA, Wax M, Leach JW et al. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: Impact of preclinical studies on clinical trial design. Eur J Cancer Suppl 2008;6:174.
    • (2008) Eur J Cancer Suppl , vol.6 , pp. 174
    • Janne, P.A.1    Wax, M.2    Leach, J.W.3
  • 47
    • 51449104064 scopus 로고    scopus 로고
    • Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
    • Tang Z, Du R, Jiang S et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008;99:911-922.
    • (2008) Br J Cancer , vol.99 , pp. 911-922
    • Tang, Z.1    Du, R.2    Jiang, S.3
  • 48
    • 79959195227 scopus 로고    scopus 로고
    • A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC)
    • Wakelee HA, Gettinger SN, Engelman JA et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(suppl 15):3017.
    • (2010) J Clin Oncol , vol.28 , Issue.15 SUPPL. , pp. 3017
    • Wakelee, H.A.1    Gettinger, S.N.2    Engelman, J.A.3
  • 49
    • 84872214179 scopus 로고    scopus 로고
    • Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC
    • Tan E, Park K, Lim WT et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011;29(suppl 15):7571.
    • (2011) J Clin Oncol , vol.29 , Issue.15 SUPPL. , pp. 7571
    • Tan, E.1    Park, K.2    Lim, W.T.3
  • 50
    • 84869499839 scopus 로고    scopus 로고
    • Phase 1 dose- escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
    • Goldman J, Laux I, Chai F et al. Phase 1 dose- escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012;118:5901-5911.
    • (2012) Cancer , vol.118 , pp. 5901-5911
    • Goldman, J.1    Laux, I.2    Chai, F.3
  • 51
    • 80052511675 scopus 로고    scopus 로고
    • Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC
    • Spigel DR, Ervin TJ, Ramlau R et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29(suppl 15):7505.
    • (2011) J Clin Oncol , vol.29 , Issue.15 SUPPL. , pp. 7505
    • Spigel, D.R.1    Ervin, T.J.2    Ramlau, R.3
  • 52
    • 80051974548 scopus 로고    scopus 로고
    • Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
    • Sequist LV, von Pawel J, Garmey EG et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29: 3307-3315.
    • (2011) J Clin Oncol , vol.29 , pp. 3307-3315
    • Sequist, L.V.1    von Pawel, J.2    Garmey, E.G.3
  • 53
    • 84859998498 scopus 로고    scopus 로고
    • Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
    • Yasenchak C, Nackaerts K, Awada A et al. Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 2010;8:126.
    • (2010) Eur J Cancer Suppl , vol.8 , pp. 126
    • Yasenchak, C.1    Nackaerts, K.2    Awada, A.3
  • 54
    • 84872214179 scopus 로고    scopus 로고
    • Randomized phase II study of ficlatuzumab (formerly AV-299), an antihepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC
    • Mok T, Tan E, Park K et al. Randomized phase II study of ficlatuzumab (formerly AV-299), an antihepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011; 29(suppl 15):TPS213.
    • (2011) J Clin Oncol , vol.29 , Issue.15 SUPPL.
    • Mok, T.1    Tan, E.2    Park, K.3
  • 55
    • 83455209245 scopus 로고    scopus 로고
    • Exploratory biomarker analyses from OAM4558g: A placebo- controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC)
    • Yu W, Pandita A, Penuel E et al. Exploratory biomarker analyses from OAM4558g: A placebo- controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(## suppl): 7529.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. , pp. 7529
    • Yu, W.1    Pandita, A.2    Penuel, E.3
  • 56
    • 84855212508 scopus 로고    scopus 로고
    • A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)
    • Sandler A, Schiller JH, Hirsh V et al. A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl 15):TPS217.
    • (2011) J Clin Oncol , vol.29 , Issue.15 SUPPL.
    • Sandler, A.1    Schiller, J.H.2    Hirsh, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.